Based on the outstanding expertise and rich experience, Creative Biolabs has specially developed a system approach of TCR generation and optimization for TCR development. With T cell persistence test techniques, our animal model construction platform can further support rapid and efficient in vivo test. Our T cell persistence test, which is fast, reliable and affordable, can be tailor-designed to meet your specific needs.
There are many requirements that need to be satisfied before the full power of T cells can be unleashed against a disease target, including the need for TCR specificity against tumor antigen, as well as the need for activation and expansion of tumor antigen-specific T cells to large numbers. Tumor- reactive T cells could be generated from peripheral blood lymphocytes (PBLs) through genetic modification with TCR genes that are isolated from effective TILs. Using TCR genes to endow specificity is that the TAA can be derived from the entire protein composition of tumor cells, such as intracellular proteins.
T cell persistence is likely to promote long-term anti-tumor effects after adoptive T cell transfer. However, a major obstacle associated with current TCRs immunotherapy is that the limited replicative lifespan of TCRs prohibits the long-term persistence and expansion of these cells in vivo, potentially hindering the long-term therapeutic effects of TCR. Here, Creative Biolabs provides an effective and safe method in vivo to improve the therapeutic potential of TCR, which can be beneficial for treating various types of cancer.
Creative Biolabs has the capability to enable you to free up your time for core work and project. Our service can be designed to meet your special needs if you have any requirements. If you are interested in our service, please contact us by E-mail and our team will get back to you as soon as possible.
Yun Bai, et al. Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA. Cell Discovery, 15040 (2015): 1-15.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE